サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1794516

神経筋疾患治療学の世界市場

Neuromuscular Disease Therapeutics

出版日
ページ情報
英文 273 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
神経筋疾患治療学の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 273 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経筋疾患治療学の世界市場は2030年までに316億米ドルに達する見込み

2024年に136億米ドルと推定される神経筋疾患治療学の世界市場は、2024～2030年の分析期間においてCAGR 15.0%で成長し、2030年には316億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである生物製剤は、CAGR16.6%を記録し、分析期間終了時には237億米ドルに達すると予想されます。低分子分野の成長率は、分析期間中CAGR 11.0%と推定されます。

米国市場は37億米ドルと推定される一方、中国はCAGR 20.2％で成長すると予測される

米国の神経筋疾患治療学市場は、2024年に37億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに69億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは20.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.9%と13.6%と予測されています。欧州では、ドイツがCAGR約12.0%で成長すると予測されています。

世界の神経筋疾患治療学市場- 主要動向と促進要因まとめ

なぜ神経筋疾患の治療に再び注目が集まっているのか？

神経筋疾患には、筋ジストロフィー、筋萎縮性側索硬化症（ALS）、脊髄性筋萎縮症（SMA）、重症筋無力症など、筋肉や筋肉を支配する神経の機能を損なう疾患群が含まれます。これらの疾患に対する注目の高まりは、診断率の上昇と、その遺伝的・分子的基盤に対する理解の拡大の両方から生じています。新生児スクリーニングや遺伝子検査によってより多くの症例が早期に発見されるようになり、効果的な治療介入に対する需要が急速に高まっています。

最近まで、治療の選択肢のほとんどは症状管理や支持療法に限られていました。しかし、遺伝子治療、アンチセンス・オリゴヌクレオチド、酵素補充戦略などの技術革新により、治療法は大きく変わりつつあります。これらの進歩は、神経筋疾患の根本原因をターゲットとし、パラダイムを緩和的アプローチから疾患修飾的解決へとシフトさせています。希少疾患や希少疾病用医薬品の開発に対する規制上の優遇措置は、新規治療法の研究をさらに加速させています。

科学的革新はどのように治療の情勢を変えているのか？

分子生物学と標的送達システムにおける画期的な進歩により、神経筋機能障害の原因となる遺伝子やタンパク質の欠陥に対処できる治療法の開発が可能になりました。脊髄性筋萎縮症に使用されるような遺伝子治療は、重要な遺伝子の機能を回復または置換することを目的とし、1回の投与で長期的な効果をもたらします。RNAレベルで遺伝子発現を変化させるように設計されたアンチセンス療法は、機能的タンパク質の産生を促進することにより、デュシェンヌ型筋ジストロフィーのような病態の治療において人気を集めています。

その他の新しいアプローチとしては、神経筋伝達の促進、免疫による神経損傷の軽減、神経筋接合部の安定化を目的としたモノクローナル抗体や低分子があります。また、幹細胞研究や神経筋再生医療も研究中であるが、その多くは臨床の初期段階にとどまっています。治療戦略の精度が高まるにつれて、患者間の疾患進行のばらつきに対処するための併用治療や個別化レジメンが評価されつつあります。

市場の進化においてヘルスケアシステムと規制機関はどのような役割を果たすのか？

医療制度や政策の枠組みは、神経筋疾患治療薬へのアクセスや償還を形成する上で重要な役割を果たしています。遺伝子治療や生物学的製剤は高価で複雑なロジスティクスを必要とするため、価格設定、承認スケジュール、長期的な転帰の追跡がますます厳しくなっています。政府と支払者は、技術革新と手頃な価格のバランスをとるために、アウトカムベースの償還モデルと実データモニタリングを模索しています。

さらに、公的機関、研究機関、バイオテクノロジー企業間のパートナーシップがパイプラインの拡充を促進しています。迅速な承認パスウェイ、ファスト・トラック指定、希少疾病用医薬品の優遇措置により、より多くの候補品がより早く市場に投入されています。しかし、特に縦断的データが限られている新規治療においては、承認後のサーベイランスと長期安全性評価が不可欠となってきています。また、希少な神経筋疾患の臨床研究やアクセス戦略を支援するために、国境を越えた共同研究や患者登録の一元化も開発されています。

神経筋疾患治療学市場の成長は、いくつかの要因によってもたらされます。

遺伝子検査やバイオマーカー検査の利用可能性が拡大することで、より早期かつ正確な診断が可能になり、より早期の疾患段階での治療介入を直接支援できるようになっています。遺伝子治療プラットフォーム、アンチセンス技術、精密生物学的製剤の進歩により、新たな治療選択肢が生まれつつあり、その多くが疾患の根本メカニズムに対処しています。希少疾患研究への資金提供の増加と有利な規制政策が、薬剤開発と国際共同臨床試験を後押ししています。患者意識の高まり、支援団体の関与、医療インフラの改善も、標的治療薬への需要を後押ししています。神経筋疾患の新生児スクリーニングの普及と送達技術の向上が、治療法の革新と市場の成長をさらに後押ししています。

セグメント

タイプ（生物製剤、低分子製剤）、エンドユーザー（病院エンドユーザー、クリニックエンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Alexion Pharmaceuticals
  • Amicus Therapeutics
  • Avidity Biosciences
  • Aquestive Therapeutics
  • Argenx SE
  • BioMarin Pharmaceutical
  • Biogen Inc.
  • Catalyst Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Roche（see F. Hoffmann-La Roche）
  • Sarepta Therapeutics Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co. Ltd.
  • Ultragenyx Pharmaceutical Inc.
  • Zydus Lifesciences Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37493

Global Neuromuscular Disease Therapeutics Market to Reach US$31.6 Billion by 2030

The global market for Neuromuscular Disease Therapeutics estimated at US$13.6 Billion in the year 2024, is expected to reach US$31.6 Billion by 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$23.7 Billion by the end of the analysis period. Growth in the Small Molecules segment is estimated at 11.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 20.2% CAGR

The Neuromuscular Disease Therapeutics market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.9 Billion by the year 2030 trailing a CAGR of 20.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.9% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.0% CAGR.

Global Neuromuscular Disease Therapeutics Market - Key Trends & Drivers Summarized

Why Is There Renewed Focus on Treating Neuromuscular Diseases?

Neuromuscular diseases encompass a group of disorders that impair the functioning of muscles and the nerves controlling them, including conditions such as muscular dystrophy, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and myasthenia gravis. Growing attention toward these conditions stems from both rising diagnosis rates and expanded understanding of their genetic and molecular underpinnings. As more cases are detected early through newborn screening and genetic testing, the demand for effective therapeutic interventions has grown rapidly.

Until recently, most treatment options were limited to symptom management or supportive care. However, innovations in gene therapy, antisense oligonucleotides, and enzyme replacement strategies are changing the therapeutic landscape. These advancements are targeting the root causes of neuromuscular conditions, shifting the paradigm from palliative approaches to disease-modifying solutions. Regulatory incentives for rare diseases and orphan drug development are further accelerating research into novel treatments.

How Are Scientific Innovations Reshaping the Treatment Landscape?

Breakthroughs in molecular biology and targeted delivery systems have enabled the development of therapies that can address defective genes or proteins responsible for neuromuscular dysfunction. Gene therapies, such as those used for spinal muscular atrophy, aim to restore or replace the function of critical genes, offering long-term benefits from a single dose. Antisense therapies, designed to alter gene expression at the RNA level, are gaining traction in treating conditions like Duchenne muscular dystrophy by promoting production of functional proteins.

Other novel approaches include monoclonal antibodies and small molecules aimed at enhancing neuromuscular transmission, reducing immune-mediated nerve damage, or stabilizing neuromuscular junctions. Stem cell research and neuromuscular regenerative medicine are also under exploration, although many remain in early clinical stages. As therapeutic strategies grow more precise, combination treatments and personalized regimens are being evaluated to address disease progression variability among patients.

What Role Do Healthcare Systems and Regulatory Bodies Play in Market Evolution?

Health systems and policy frameworks are playing a vital role in shaping access and reimbursement for neuromuscular disease therapies. Due to the high cost and complex logistics of gene and biologic therapies, pricing, approval timelines, and long-term outcome tracking have come under increased scrutiny. Governments and payers are exploring outcomes-based reimbursement models and real-world data monitoring to balance innovation with affordability.

Additionally, partnerships between public agencies, research institutions, and biotechnology firms are fostering pipeline expansion. Accelerated approval pathways, fast-track designations, and orphan drug incentives are helping more candidates reach the market faster. However, post-approval surveillance and long-term safety evaluations are becoming essential, especially for novel treatments with limited longitudinal data. Cross-border collaborations and centralized patient registries are also being developed to support clinical research and access strategies for rare neuromuscular conditions.

Growth in the neuromuscular disease therapeutics market is driven by several factors.

Expanding availability of genetic and biomarker testing is enabling earlier and more accurate diagnosis, directly supporting therapeutic intervention at earlier disease stages. Advances in gene therapy platforms, antisense technologies, and precision biologics are generating new treatment options, many of which address the disease’s root mechanisms. Increased funding in rare disease research, along with favorable regulatory policies, is encouraging drug development and global clinical trials. Rising patient awareness, advocacy group engagement, and improvements in care infrastructure are also boosting demand for targeted therapeutics. Broader adoption of newborn screening for neuromuscular disorders and improvements in delivery technologies are further supporting therapeutic innovation and market growth.

SCOPE OF STUDY:

The report analyzes the Neuromuscular Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Biologics, Small Molecules); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Alexion Pharmaceuticals
  • Amicus Therapeutics
  • Avidity Biosciences
  • Aquestive Therapeutics
  • Argenx SE
  • BioMarin Pharmaceutical
  • Biogen Inc.
  • Catalyst Pharmaceuticals
  • F. Hoffmann-La Roche Ltd
  • Ionis Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Roche (see F. Hoffmann-La Roche)
  • Sarepta Therapeutics Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co. Ltd.
  • Ultragenyx Pharmaceutical Inc.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Neuromuscular Disease Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Neuromuscular Disorders Drives Demand for Targeted Therapeutic Interventions
    • Advances in Gene Therapy Propel Development of Disease-Modifying Treatments for NMDs
    • Increased Regulatory Support for Rare Disease Therapies Strengthens Drug Development Pipeline
    • Expanding Clinical Trials for ALS, DMD, and SMA Accelerate Innovation in Neuromuscular Therapeutics
    • Emergence of RNA-Based Therapies Spurs Breakthroughs in Precision Neuromuscular Medicine
    • High Unmet Clinical Need in Pediatric Neuromuscular Disorders Expands Addressable Market
    • Growing Adoption of Monoclonal Antibodies Enhances Treatment Options for Autoimmune NMDs
    • Rise in Patient Advocacy and Funding Initiatives Drives Acceleration of Research and Commercialization
    • Advancements in Biomarker Discovery Support Early Diagnosis and Therapeutic Monitoring
    • Use of Digital Health and Wearable Devices Enables Real-Time Assessment of Disease Progression
    • FDA and EMA Orphan Drug Designations Generate Momentum for Neuromuscular Therapies
    • Adoption of Combination Therapy Approaches Expands Efficacy in Progressive NMD Cases
    • Rapid Growth in Personalized Medicine Drives Tailored Approaches to Neuromuscular Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Neuromuscular Disease Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Neuromuscular Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Neuromuscular Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Neuromuscular Disease Therapeutics by Type - Biologics and Small Molecules Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Neuromuscular Disease Therapeutics by Type - Percentage Breakdown of Value Sales for Biologics and Small Molecules for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Neuromuscular Disease Therapeutics by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Neuromuscular Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION